Lisata Therapeutics Inc

Lisata Therapeutics, Inc. develops biopharmaceuticals. It is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. It is designed to modify the tumor microenvironment by activating a novel uptake pathway that allows anti-cancer drugs to penetrate solid tumors more effectively. The company is headquartered in Basking Ridge, NJ.

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Lisata Therapeutics advances certepetide, poised to revolutionize cancer treatment

Lisata Therapeutics' Q1 2024 performance reflects prudent financial management and promising advancements in certepetide's clinical development
Despite challenges in meeting trial milestones and reshaping oncology standards, the company's strengths in regulatory support and safety profile offer a competitive edge
Opportunities lie in certepetide's potential to redefine cancer treatment paradigms, with successful trials paving the way for market leadership and global expansion

Lisata Therapeutics reports improved Q2 performance and advances in oncology

Lisata Therapeutics showed improved financial performance in Q2 2024 with reduced operating expenses and a strong cash position.
The progress on Certepetide underscores the company's commitment to innovative R&D and potential breakthroughs in advanced solid tumor treatments.
While facing challenges such as net losses and competitive pressures, Lisata Therapeutics has opportunities to drive growth through strategic partnerships and clinical trial advancements.

Lisata Therapeutics advances certepetide in cancer and endometriosis treatments

Lisata Therapeutics showcased progress in certepetide's cancer treatment and endometriosis exploration, despite a net loss in Q3 2024. The company faces challenges in aligning market perception with its promising pipeline but has opportunities for growth through ongoing trials and strategic partnerships.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Lisata Therapeutics, Inc. is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to target and penetrate tumors. It also actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs more efficiently penetrating and accumulating in the tumor, while normal tissues are unlikely to be affected. The company was founded in 1980 and is headquartered in Basking Ridge, NJ.

Lisata Therapeutics Inc (NASDAQ:LSTA) has been awarded the title of ‘Specialized BioTherapeutics Company of the Year' at the 2024 BioTech Breakthrough Awards. The company said it was recognized for its unique approach to addressing the unmet medical needs of patients with advanced solid tumors, particularly through its proprietary CendR Platform technology which enhances the delivery and efficacy of anti-cancer treatments by targeting the tumor microenvironment.

Lisata Therapeutics named ‘Specialized BioTherapeutics Company of the Year' at 2024 BioTech Breakthrough Awards

Award recognizes Lisata's data-driven approach and innovative therapies designed to address the unmet medical needs of patients with advanced solid tumors

Lisata Therapeutics Wins 2024 BioTech Breakthrough Award for ‘Specialized BioTherapeutics Company of the Year'

Lisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazzo joined Proactive to talk about the latest updates on its clinical trials and its third quarter financial performance. Mazzo highlighted advancements in Lisata's pancreatic cancer program, specifically the ASCEND trial, which is expected to yield important data soon.

Lisata Therapeutics CEO discusses pancreatic cancer trial progress and new collaborations - ICYMI

Lisata Therapeutics, Inc. (NASDAQ:LSTA ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants John Menditto - VP, IR & Corporate Communications David Mazzo - President, CEO & Director James Nisco - SVP, Finance, Treasurer, CAO & Principal Financial and Accounting Officer Kristen Buck - EVP, R&D & Chief Medical Officer Conference Call Participants Steve Brozak - WBB Securities Pete Enderlin - MAZ Partners Will Hidell - Brookline Capital Markets Operator Welcome to the Lisata Therapeutics' Third Quarter 2024 Financial Results and Business Update Conference Call. [Operator Instructions] As a reminder, this call is being recorded today, Tuesday, November 12, 2024.

Lisata Therapeutics, Inc. (LSTA) Q3 2024 Earnings Call Transcript

Lisata Therapeutics Inc (NASDAQ:LSTA) reported significant advancements across its clinical portfolio in the third quarter, with multiple key data readouts projected over the next 18 months. Lisata's financial performance for the quarter showed a 10.5% year-over-year decrease in operating expenses, down to $5.3 million from $6 million.

Lisata Therapeutics advances clinical trials in Q3 ahead of 'data-rich' 2025

Robust and expanding development portfolio with multiple key data readouts projected over the next 18 months Conference call scheduled for today at 4:30 p.m. Eastern Time BASKING RIDGE, N.J.

Lisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Lisata Therapeutics Inc (NASDAQ:LSTA), the US-based clinical-stage pharmaceutical company, and Finnish immunotherapy developer Valo Therapeutics Oy have announced a preclinical research collaboration to explore a novel cancer treatment combination targeting melanoma. Under the collaboration, Valo Therapeutics will lead research investigating the potential benefits of combining Lisata's experimental drug, certepetide, with Valo's PeptiCRAd immunotherapy platform and a checkpoint inhibitor.

Lisata Therapeutics and Valo Therapeutics partner in preclinical study on cancer immunotherapy

Study will investigate the benefits of combining Lisata's novel product candidate, certepetide, with ValoTx's platform technology, PeptiCRAd, and a checkpoint inhibitor in preclinical tumor models Study will investigate the benefits of combining Lisata's novel product candidate, certepetide, with ValoTx's platform technology, PeptiCRAd, and a checkpoint inhibitor in preclinical tumor models

Lisata Therapeutics and Valo Therapeutics Announce Preclinical Research Collaboration

BASKING RIDGE, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the Company will report its financial results for the third quarter ended September 30, 2024, on Tuesday, November 12, 2024, after the close of trading and will host a conference call at 4:30 p.m. Eastern time.

Lisata Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update on Tuesday, November 12, 2024

Lisata Therapeutics Inc (NASDAQ:LSTA) chief medical officer Dr Kristen Buck discussed with Proactive a promising collaboration between the company and the University of Cincinnati aimed at investigating an endometriosis treatment. Dr Buck highlighted Certepetide, Lisata's novel cyclic peptide therapeutic that targets integrins and neuropilin receptors, which are notably elevated in both solid tumors and endometriosis.

Lisata Therapeutics partners with University of Cincinnati to investigate endometriosis therapy - ICYMI

Lisata Therapeutics, Inc. (LSTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Lisata Therapeutics, Inc. (LSTA) Upgraded to Buy: Here's What You Should Know

BASKING RIDGE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that management will participate at the following events in November:

Lisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor Events

Lisata Therapeutics Inc (NASDAQ:LSTA) has entered a research agreement with the University of Cincinnati to study the use of its cyclic peptide, certepetide, combined with the VEGF inhibitor bevacizumab, for treating endometriosis in a preclinical animal model. Under the new partnership, the University of Cincinnati will lead the research, with Lisata providing funding and its novel therapy, certepetide.

Lisata Therapeutics strikes research partnership to investigate new treatment for endometriosis

Strategic partnership explores therapeutic effect of Lisata's novel cyclic peptide product candidate, certepetide, in combination with bevacizumab Strategic partnership explores therapeutic effect of Lisata's novel cyclic peptide product candidate, certepetide, in combination with bevacizumab

Lisata Therapeutics Announces Sponsored Preclinical Research Agreement with the University of Cincinnati to Study Certepetide for the Treatment of Endometriosis

Lisata Therapeutics Inc (NASDAQ:LSTA) announced that it has started treatment of the first patient in the second-line cholangiocarcinoma (CCA) cohort of its BOLSTER trial. CCA, also known as bile duct cancer, has a five-year survival rate less than 5%, highlighting the urgent need for new and effective treatments.

Lisata Therapeutics begins treating second cohort of patients in bile duct cancer trial

BASKING RIDGE, N.J. , Sept. 09, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that management will present at the following events in September:

Lisata Therapeutics to Participate in Upcoming September 2024 Industry and Investor Events

Lisata Therapeutics Inc (NASDAQ:LSTA) announced today that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to its investigational product, certepetide, for the treatment of cholangiocarcinoma. Cholangiocarcinoma, a rare and aggressive form of cancer affecting the bile ducts, presents a significant challenge due to the limited effectiveness of current treatment options, particularly in advanced stages.

Lisata Therapeutics' certepetide receives Orphan Drug Designation for cholangiocarcinoma

BASKING RIDGE, N.J., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Orphan Drug Designation to certepetide for the treatment of cholangiocarcinoma.

Lisata Therapeutics' Certepetide Granted FDA Orphan Drug Designation for the Treatment of Cholangiocarcinoma

Lisata Therapeutics, Inc. (NASDAQ:LSTA) Q2 2024 Earnings Conference Call August 12, 2024 4:30 AM ET

Lisata Therapeutics, Inc. (LSTA) Q2 2024 Earnings Call Transcript

Lisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazzo told shareholders that the company is coming off a quarter with “strong momentum” to advance clinical studies on its investigational product, certepetide. The biotech firm is looking forward to crucial data readouts from ongoing trials, particularly the Phase 2b ASCEND trial, which could lead to transformative outcomes and potential regulatory approvals.

Lisata Therapeutics coming off strong 2Q performance, CEO says

Lisata Therapeutics Inc (NASDAQ:LSTA) chief medical officer Kristen Buck joined Proactive to discuss the company's new research collaboration with Haystack Oncology which will evaluate the efficacy of its drug candidate certepetide as a therapy for pancreatic cancer. She detailed the collaboration, which will leverage Haystack's minimal residual disease (MRD) technology to detect circulating tumor DNA in blood, which can indicate cancer recurrence or progression.

Lisata Therapeutics CMO details pancreatic cancer research collaboration with Haystack Oncology - ICYMI

Lisata Therapeutics Inc (NASDAQ:LSTA) has announced a research collaboration with Haystack Oncology using Haystack's MRD technology to evaluate the efficacy of its investigational pancreatic cancer therapy certepetide. Per the research agreement, Lisata will deploy the Haystack MRD technology for the detection of circulating tumor DNA (ctDNA) in a clinical study evaluating certepetide plus chemotherapy as an investigational treatment for metastatic pancreatic cancer.

Lisata Therapeutics partners with Haystack Oncology to advance pancreatic cancer therapy research

BALTIMORE, Md. and BASKING RIDGE, N.J., July 18, 2024 (GLOBE NEWSWIRE) -- Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, and Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced a research collaboration. Lisata will deploy the highly sensitive Haystack MRD™ technology for the detection of circulating tumor DNA (ctDNA) in a clinical study evaluating certepetide plus chemotherapy as an investigational treatment for metastatic pancreatic cancer.

Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD™ Technology to Evaluate Efficacy of Pancreatic Cancer Therapy

Lisata (LSTA) is progressing well with developing its lead investigational pipeline candidate, certepetide, which is being studied for various cancer indications.

Lisata (LSTA) Stock Rallies More Than 30% YTD: Here's Why

Lisata Therapeutics Inc (NASDAQ:LSTA) said it has completed enrollment in its Phase 2a BOLSTER trial for certepetide, a promising investigational treatment for first-line cholangiocarcinoma (CCA). The BOLSTER trial, a Phase 2a double-blind, placebo-controlled study conducted across multiple centers in the United States, evaluates certepetide in combination with standard-of-care versus standard-of-care alone for patients with first-line CCA.

News for Lisata Therapeutics Inc Stock (LSTA)